Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BACKGROUND: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting two...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer
Asıl Yazarlar: Atefi, Mohammad, Titz, Bjoern, Avramis, Earl, Ng, Charles, Wong, Deborah JL, Lassen, Amanda, Cerniglia, Michael, Escuin-Ordinas, Helena, Foulad, David, Comin-Anduix, Begonya, Graeber, Thomas G, Ribas, Antoni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320814/
https://ncbi.nlm.nih.gov/pubmed/25645078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0293-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller